Bioxytran (BIXT) Common Equity (2010 - 2026)
Bioxytran (BIXT) posted Common Equity of -$4.4 million for Q1 2026, down 69.6% sequentially from -$2.6 million in Q4 2025, and down 62.29% YoY from -$11.7 million in Q1 2025.
Bioxytran (BIXT) Common Equity (2010 - 2026) Analysis & Trends
Bioxytran has reported Common Equity for 17 years, with the latest figure at -$4.4 million in Q1 2026.
- Quarterly Common Equity fell 62.29% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.4 million (down 62.29% YoY) and the FY2025 annual result came in at -$2.6 million, down 44.61% from the prior year.
- Common Equity slipped to -$4.4 million in Q1 2026 per BIXT's latest filing, from -$2.6 million in the prior quarter.
- Over five years, Common Equity peaked at -$990424.0 in Q1 2024 and troughed at -$4.8 million in Q2 2022.
- A 5-year average of -$2.8 million and a median of -$2.7 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity sank 264.14% in 2022, then soared 75.61% in 2024.
- Over 5 years, Common Equity stood at -$3.3 million in 2022, then climbed by 5.83% to -$3.1 million in 2023, then jumped by 42.29% to -$1.8 million in 2024, then tumbled by 44.61% to -$2.6 million in 2025, then tumbled by 69.6% to -$4.4 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$4.4 million, -$2.6 million, and -$2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | -4.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.39 Mn |
| Dec 31, 2025 | -2.59 Mn |
| Sep 30, 2025 | -2.90 Mn |
| Jun 30, 2025 | -2.64 Mn |
| Mar 31, 2025 | -2.71 Mn |
| Dec 31, 2024 | -1.79 Mn |
| Sep 30, 2024 | -1.08 Mn |
| Jun 30, 2024 | -1.10 Mn |
| Mar 31, 2024 | -990,424.00 |
| Dec 31, 2023 | -3.10 Mn |
| Sep 30, 2023 | -2.14 Mn |
| Jun 30, 2023 | -2.66 Mn |
| Mar 31, 2023 | -4.06 Mn |
| Dec 31, 2022 | -3.30 Mn |
| Sep 30, 2022 | -2.55 Mn |
| Jun 30, 2022 | -4.76 Mn |
| Mar 31, 2022 | -4.08 Mn |
| Dec 31, 2021 | -3.16 Mn |
| Sep 30, 2021 | -1.92 Mn |
| Jun 30, 2021 | -1.31 Mn |